March 12, 2018 - Metabolix, Inc. (NASDAQ:YTEN) has filed a financial statement reporting Revenues of $944,000 USD. Previously, on March 30, 2017, Metabolix, Inc. reported Revenues of $1,159,000 USD. This represents a change of -18.55% in Revenues.

Period EndPeriodValue
2017-12-31 2017-A 944,000
2016-12-31 2016-A 1,159,000
2015-12-31 2015-A 2,594,000
2014-12-31 2014-A 2,800,000
2013-12-31 2013-A 3,778,000
2012-12-31 2012-A 41,381,000

Other Interesting Charts

Cost Of Revenue Research And Development Expenses - Costs And Expenses - Deferred Tax Assets Capitalized Research And Development Expenses - Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost - Effective Income Tax Rate Reconciliation Nondeductible Expense - Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost - Income Tax Expense Benefit - Increase Decrease In Deferred Revenue - Increase Decrease In Prepaid Deferred Expense And Other Assets - Operating Leases Rent Expense Net - Other Nonoperating Income Expense - Prepaid Expense And Other Assets Current - Revenue From Grants - Revenue From Related Parties - Revenue Product Sales To Related Party - Revenues - Sales Revenue Net - Selling General And Administrative Expense - Stock Offering Costs Remaining In Account Payable And Accrued Expenses -

Related News Stories

Yield10 Bioscience, Inc. (YTEN) CEO Oliver Peoples on Q2 2018 Results - Earnings Call Transcript

2018-08-10 seekingalpha
Yield10 Bioscience, Inc. (NASDAQ:YTEN) Q2 2018 Results Earnings Conference Call August 9, 2018 4:30 PM ET (0-1)

Arcadia Biosciences:  A Speculative Pure-Play In The Genome Editing Agricultural Space

2018-07-16 seekingalpha
I highlight a number of reasons why I've taken a speculative position in RKDA, including commercialization prospects and cash on hand relative to historical burn rates. (5-3)

CUSIP: 591018809